Latest Mergers And Acquisitions News

XRF Scientific posted a 13.8% jump in March quarter revenue to $15.8 million, led by strong international sales and new product shipments. The newly operational India office marks a strategic expansion, setting the stage for further growth.

AuMEGA Metals has closed a C$30.1 million financing round, bolstering its institutional shareholder base and fully funding an expanded 2026 exploration program across its Newfoundland projects.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

WhiteHawk Limited has raised A$1.5 million through a share placement to fund integration and growth of its newly acquired Quixxi Clarity AI platform, marking a strategic push into the AI governance market.

Xenitra Limited has acquired Hong Kong Fukang Trading Co., including key pharmaceutical licenses and ecommerce assets, to fully operationalise its OTC medicine business in Hong Kong and China.

Qoria Limited and Aura have pushed back their merger timeline to July 2026 amid transaction complexities, with Aura providing a A$10 million unsecured working capital facility to support Qoria through the interim period.

Wildcat Resources (ASX: WC8) has expanded its Bolt Cutter Central lithium discovery footprint beyond 2.3km with multiple high-grade spodumene intercepts, while advancing the Definitive Feasibility Study for its Tabba Tabba Project. The company maintains a strong cash position of A$43.3 million as it prepares for further drilling and development milestones.

Duratec's joint venture with Ertech has clinched a $281 million contract to upgrade submarine infrastructure at HMAS Stirling, marking a major step in Australia's AUKUS defence preparations.

Cuscal Limited has successfully raised A$30 million through a fully underwritten institutional placement to fund its acquisition of Paymark. The company also launched a Share Purchase Plan targeting an additional A$3 million from eligible shareholders.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

Cobre Limited has kicked off a major 40,000-metre drilling campaign at its Sierra Atacama copper project in Chile, aiming to convert its existing NI 43-101 resource to JORC compliance and explore opportunities for a larger open-pit operation.

Cavalier Resources’ 2026 Pre-Feasibility Study update boosts the Stage 1 NPV of its Crawford Gold Project to A$77.2 million at A$6,500/oz gold, reflecting resilience amid supply chain pressures. The project maintains its ore reserve and pit design, with financing negotiations advancing.